Ductal carcinoma in situ (DCIS) now represents 20–25% of all 'breast cancers' consequent
upon detection by population-based breast cancer screening programmes. Currently, all …

Ductal carcinoma in situ (DCIS) is a nonobligate precursor of invasive cancer, and its
detection, diagnosis, and management are controversial. DCIS incidence grew with the …

The COVID-19 pandemic presents clinicians a unique set of challenges in managing breast
cancer (BC) patients. As hospital resources and staff become more limited during the COVID …

Background Approximately 15% of all breast cancers occur in women with a family history of
breast cancer, but for whom no causative hereditary gene mutation has been found …

With the widespread adoption of population-based breast cancer screening, ductal
carcinoma in situ (DCIS) has come to represent 20–25% of all breast neoplastic lesions …

Purpose The aim of this study is to explore new salivary biomarkers to discriminate breast
cancer patients from healthy controls. Methods Saliva samples were collected after 9 h …

Background Third-generation aromatase inhibitors are more effective than tamoxifen for
preventing recurrence in postmenopausal women with hormone-receptor-positive invasive …

Background The vast majority of women diagnosed with ductal carcinoma in situ (DCIS)
undergo treatment. Therefore, the risks of invasive progression and competing death in the …

Background: Biennial screening is generally recommended for average-risk women aged
50 to 74 years, but tailored screening may provide greater benefits. Objective: To estimate …

Introduction The rapid spread of COVID‐19 across the globe is forcing surgical oncologists
to change their daily practice. We sought to evaluate how breast surgeons are adapting their …